Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring

company
Nov.18
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands disclosed on November 17, 2026, that its global manufacturing and organisational restructuring is expected to reduce between 4,200 and 4,600 roles by the end of 2030, equivalent to approximately 16%–18% of its workforce at the end of 2025. The first phase covers 2,100 roles with departures confirmed or subject to consultation, while a further 2,100–2,500 positions are expected to be eliminated by 2030. The company is proceeding with the closure of its Langenhagen factory in Germany, has sold its manufacturing facility in Taiwan, and has transferred selected finance, procurement and supply-chain operations in Poland to Capgemini. The restructuring programme is expected to cost approximately £740 million, with Imperial targeting at least £320 million in annual cost savings by 2030.

Key Points

  • Imperial Brands expects cumulative reductions of 4,200–4,600 roles by 2030, equivalent to approximately 16%–18% of its 25,800 employees at the end of 2025.
  • The first 2,100 departures have been confirmed or remain under consultation, with a further 2,100–2,500 roles expected to be eliminated by 2030.
  • The company is closing its Langenhagen plant in Germany, has sold its Taiwan factory for £54 million, and transferred selected Polish support operations to Capgemini.
  • Imperial recognised £327 million in fiscal 2026 restructuring costs, including £49 million in severance costs.
  • The programme is expected to cost approximately £740 million in total. Imperial delivered £90 million in annualised savings in fiscal 2026 and targets at least £320 million a year by 2030.

2Firsts

November 18, 2026

Imperial Brands plans to cut up to 4,600 jobs worldwide by the end of 2030, equivalent to nearly 18% of its workforce at the end of 2025, as the British tobacco group closes conventional tobacco manufacturing facilities, disposes of production assets, transfers support operations and expands the use of digital technology.

The company said in its November 17 fiscal 2026 results and investor presentation that the first phase covers 2,100 roles with departures confirmed or still under consultation. A further 2,100–2,500 positions are expected to be eliminated by the end of 2030, bringing the cumulative reduction to between 4,200 and 4,600 roles.

Imperial is targeting annual cost savings of at least £320 million (approximately $420 million) by 2030 through a restructuring programme expected to cost around £740 million.

Chief Executive Lukas Paravicini told reporters that the changes were intended to improve efficiency while making the group more data-driven, faster at innovation and more responsive to changing consumer demand, according to Reuters.

Up to 4,600 Roles Targeted as Restructuring Extends Through 2030

The job reductions form part of Imperial Brands' 2030 Strategy, announced in March 2025, covering manufacturing, procurement, logistics, corporate support functions and digital technology.

According to the company's fiscal 2026 investor presentation, the first phase covers approximately 2,100 roles, with departures either confirmed or under consultation. That figure does not mean all affected employees have already left the business.

Imperial expects to eliminate a further 2,100–2,500 roles by the end of 2030.

Based on its workforce of approximately 25,800 employees at the end of 2025, the combined reductions represent around 16%–18% of the group.

Sky News reported that the initial restructuring includes manufacturing facilities in Germany and Taiwan, involving approximately 700 employees. The Langenhagen plant in Germany alone employed around 640 workers when the closure plan was announced.

Imperial has not published a complete country-by-country or business-unit breakdown of the further planned reductions. Sky News reported that UK employees are expected to account for a relatively small proportion of the cuts.

The company said the changes would proceed under applicable employee consultation procedures.

German Plant Closure and Taiwan Factory Disposal Reshape Manufacturing Network

Manufacturing consolidation is a significant component of Imperial's restructuring programme.

In October 2025, the company announced plans to cease production at the Langenhagen factory in Germany, operated by its subsidiary Reemtsma. The facility manufactured conventional tobacco products and employed approximately 640 people at the time.

Imperial cited the long-term decline in demand and production volumes for combustible tobacco products, resulting in lower utilisation of manufacturing capacity.

During fiscal 2026, the group completed employee consultations relating to the Langenhagen closure and continued preparations for ceasing operations and managing the site.

The latest financial statements estimate total closure costs of approximately £220 million, including £182 million recognised in fiscal 2026.

The fiscal 2026 amount comprises £77 million in provisions for employee-related costs, a £69 million retirement benefit liability, £18 million in site decommissioning provisions and £18 million in project, legal, consultancy and machinery relocation costs.

Separately, Imperial recognised a £101 million impairment charge against the factory's assets in fiscal 2025. That charge is in addition to the estimated £220 million closure cost.

In Asia, Imperial completed the disposal of its Taiwan manufacturing facility during fiscal 2026. The transaction included land, buildings and machinery, generating £54 million in proceeds.

The company recognised a £27 million gain on the disposal and £11 million in costs associated with subsequently exiting the site.

The Taiwan transaction involved the sale of manufacturing assets. Imperial did not announce a complete withdrawal from the Taiwanese tobacco market.

Imperial's conventional tobacco volumes declined 3.4% in fiscal 2026 to 180.6 billion stick equivalents. The group attributed part of the reduction to lower private-label production in Germany and weaker demand in European tobacco markets.

Capgemini Takes Over Polish Support Operations as Shared Services and AI Expand

Imperial is also reorganising finance, procurement, supply-chain management and other corporate support functions.

In February 2026, the company announced a partnership with French technology and consulting group Capgemini. In April, Imperial transferred its finance, procurement and supply-chain hubs in Poland to Capgemini, recognising a £28 million gain on the transaction during the fiscal year.

The partnership includes an Intelligent Business Hub through which Capgemini will manage selected shared services for Imperial's business units and geographic markets.

The Guardian reported that approximately 400 positions in Poland were associated with the transfer of support functions. Imperial has not separately disclosed how many of those employees were made redundant.

Alongside the outsourcing arrangement, the tobacco group is upgrading its enterprise resource planning (ERP) systems, with new platforms deployed in Australasia and at the Radom manufacturing site in Poland.

Imperial has also introduced an AI-powered sales assistant for teams in Europe and the United States. Its November 17 investor presentation said the tool could reduce sales preparation time by up to one-third.

The Capgemini partnership also covers enterprise data management, process automation and artificial intelligence.

Imperial has not disclosed how many jobs within its wider restructuring programme are being directly replaced by AI systems.

£740 Million Programme Targets at Least £320 Million in Annual Savings by 2030

Imperial estimates the total cost of its 2030 Strategy restructuring programme at approximately £740 million, including around £600 million in cash costs and £140 million in non-cash charges.

Approximately £500 million of the cash expenditure is expected to fall in fiscal 2027 and fiscal 2028.

In fiscal 2026, the company recognised £327 million in costs associated with the programme, while cash expenditure amounted to £118 million.

The recognised costs comprised £182 million related to the Langenhagen factory closure and £145 million associated with wider organisational changes.

The £145 million of organisational costs included £49 million in severance expenses, £26 million for internal programme staff, £26 million for external partner support and £44 million in other costs.

Imperial said it delivered approximately £90 million in annualised savings in fiscal 2026, including around £25 million from manufacturing improvement initiatives. Additional savings came from procurement, production planning, logistics and optimisation of the manufacturing footprint.

Measures implemented since the 2030 Strategy began are expected to support approximately £180 million in future annualised savings, including the £90 million already delivered.

The group's target is to increase annual savings to at least £320 million by 2030.

The programme is taking place as Imperial's conventional tobacco business faces continued volume pressure. Fiscal 2026 tobacco volumes declined 3.4%, but pricing increased 5.1%, allowing tobacco net revenue to rise 1.7% at constant currency.

Meanwhile, net revenue from next-generation products (NGP), including blu vaping products, Pulze heated tobacco devices and zone nicotine pouches, increased 11.4% at constant currency. The NGP business nevertheless recorded an adjusted operating loss of £63 million.

Imperial has not disclosed the full allocation of planned job reductions among combustible tobacco operations, next-generation nicotine businesses and corporate shared services.

Follow 2Firsts for developments in global tobacco companies' restructuring, manufacturing operations, next-generation nicotine products and corporate strategies.

Cover Image:Imperial Brands

Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
The White House withdrew Heidi Overton's nomination to lead the U.S. Food and Drug Administration (FDA) on November 17, 2026, a day before a scheduled Senate committee vote. Overton faced questions from Republican and Democratic senators over vaccines, abortion medication and flavored nicotine products. In May, the FDA granted its first marketing authorizations for non-tobacco, non-menthol e-cigarette flavors, including mango and blueberry pods from Glas. Republican Senator Susan Collins challenged recent authorizations for flavored vaping and nicotine pouch products during Overton's September confirmation hearing. The FDA remains under Acting Commissioner Kyle Diamantas.
FDA
Nov.18
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27